BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough (“RCC”) and other cough hypersensitivity indications, today announced that three late-breaking abstracts reviewing clinical data from the Phase 2b SOOTHE trial will be presented at the upcoming American Thoracic Society (ATS) 2022 International Conference, being held in San Francisco, CA from May 13-18, 2022.

Mini Symposium Details: Title: Safety and Efficacy of BLU-5937 in the Treatment of Refractory Chronic Cough from the Phase 2b Soothe Trial Session: Session C93 - Clinical Trials in Chronic Lung Disease Date/Time: Tuesday, May 17, 2022, 6:35-6:45 p.m. ET/3:35-3:45 p.m. PT

Poster Presentation Details: Title: Responders Analyses in Objective 24H Cough Frequency in Soothe, A Phase 2b Trial of a Selective P2x3 Antagonist in Refractory Chronic Cough Session: Session B40 - Assessment and Treatment of Cough and Dyspnea Date/Time: Monday, May 16, 2022, 2:15-4:15 p.m. ET/11:15-1:15 p.m. PT

Title: Improvements in Cough Severity and Quality of Life in SOOTHE, A Phase 2b, Dose Finding Trial of BLU-5937 in Refractory Chronic Cough Session: Session B40 - Assessment and Treatment of Cough and Dyspnea Date/Time: Monday, May 16, 2022, 2:15-4:15 p.m. ET/11:15-1:15 p.m. PT

The three late-breaking abstracts are currently available on the ATS website here. Following the conference, the presentation materials will be available in the “Scientific Publications” section of BELLUS Health's website at www.bellushealth.com.

About BELLUS Health (www.bellushealth.com)

BELLUS Health is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of RCC and other cough hypersensitivity indications. The Company's product candidate, BLU-5937, has successfully completed a Phase 2b trial in RCC. BELLUS is planning a Phase 3 program, which is expected to begin in the second half of 2022.

Chronic cough is a cough lasting longer than eight weeks and when the cause of chronic cough cannot be identified or the cough persists despite treatment of all identified associated causes, the condition is referred to as RCC. It is estimated that there are approximately 9 million patients in the United States suffering from RCC. RCC is associated with significant adverse physical, social, and psychosocial effects on health and quality of life. Currently, there is no specific therapy approved for RCC and treatment options are limited.

The Company is exploring the potential use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

FOR MORE INFORMATION, PLEASE CONTACT: Ramzi Benamar Chief Financial Officer rbenamar@bellushealth.com

Media: Julia Deutsch Solebury Trout jdeutsch@soleburytrout.com

BELLUS Health (TSX:BLU)
Historical Stock Chart
Von Nov 2024 bis Dez 2024 Click Here for more BELLUS Health Charts.
BELLUS Health (TSX:BLU)
Historical Stock Chart
Von Dez 2023 bis Dez 2024 Click Here for more BELLUS Health Charts.